Advancing Treatment for Cystic Fibrosis Airway Inflammation

Cystic fibrosis (CF) remains a complex genetic condition where chronic lung disease and persistent hyper-inflammation drive morbidity. Researchers recently investigated a novel therapeutic approach to address cystic fibrosis airway inflammation using repurposed agents. Specifically, they evaluated inhalable Nano into Micro (NiM) formulations carrying Iloprost (ILO), a prostacyclin analogue known for its potent anti-inflammatory properties.

The study utilized advanced pre-clinical models. Specifically, cells were isolated from 15 individuals with CF carrying the F508del mutation. These cells underwent conditional reprogramming and differentiation into a mucociliary epithelium. This air-liquid interface (ALI) culture effectively mimicked the human airway. Consequently, the researchers could test the efficacy of NiM formulations under realistic conditions. They found that NiM-PEG-ILO significantly reduced the mRNA levels of several critical pro-inflammatory cytokines, including TNF-α, IL-6, IL-8, and IL-1β.

Mechanisms of Action in Cystic Fibrosis Airway Inflammation Control

Beyond cytokine suppression, the formulation achieved a marked downregulation of microRNAs associated with inflammatory pathways. Specifically, levels of miR-145, miR-146a, and miR-17 decreased relative to the control group. This dual-action approach targets both the protein-level mediators and the upstream genetic regulators of cystic fibrosis airway inflammation. Moreover, cytofluorimetry confirmed that the cells internalized both pegylated and non-pegylated nanoparticles in a concentration-dependent manner.

The NiM-based delivery system provides a distinct advantage by potentially overcoming the thick mucus barriers characteristic of CF lungs. Furthermore, pegylation of the nanoparticles enhances their stability and diffusion. Ultimately, these results suggest that inhalable ILO-loaded NiM formulations could serve as a powerful tool for attenuating the unremitting inflammatory response in the CF airway.

Frequently Asked Questions

What are NiM formulations?

Nano into Micro (NiM) formulations are drug delivery systems where nanoparticles are embedded into microparticles. This design facilitates efficient inhalation and allows the medication to bypass physiological barriers like thick mucus.

Why was Iloprost chosen for this study?

Iloprost is a prostacyclin analogue traditionally used for pulmonary arterial hypertension. It was repurposed here because of its ability to modulate the inflammatory response and reduce cytokine production in airway cells.

Which cytokines did the treatment affect?

The treatment with NiM-PEG-ILO significantly reduced the mRNA levels of TNF-α, IL-6, IL-8, and IL-1β, which are all primary drivers of inflammation in cystic fibrosis.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Carbone A et al. Iloprost-loaded inhalable Nano into Micro (NiM) formulations for treating hyper-inflammation in a pre-clinical model of cystic fibrosis airway epithelial cells. Drug Deliv Transl Res. 2026 Mar 21. doi: 10.1007/s13346-026-02101-0. PMID: 41865230.

Carbone A, et al. Downregulation of inflammatory cytokines and miRNAs by novel inhalable formulations bearing Iloprost in primary human cystic fibrosis nasal epithelial cells. Journal of Cystic Fibrosis. 2025. doi: 10.1016/j.jcf.2025.03.550.

Craparo EF, et al. Lung Disease Management by Iloprost-Loaded Nanoparticles to Address Hyperinflammation Associated with Cystic Fibrosis. ACS Applied Nano Materials. 2024. doi: 10.1021/acsanm.4c01379.